Podcasts about association international conference

This September episode of “Caregiving Club On Air” we focus on World Alzheimer's Month as well as National Falls Prevention Week (Sept 23-28) with our guest, Steve Popovich, CEO/President of Theora Care. Steve will share how Theora Care's technology is helping to detect and prevent falls for older adults and helping recover Alzheimer's adults who have wandered. (4:56) For CAREGIVER WELLNESS NEWS, Sherri shares the latest research news from the Alzheimer's Association International Conference including how wildfires, processed meat may increase your dementia risk and how blood tests can be used to diagnosis Alzheimer's – and much more! Sherri also features our Pop Culture segment with her review of the movie, “Reagan” about the former president who had Alzheimer's at the end of his life. (24:52) -Interview with Steve Popovich, CEO/President, Theora Care (1:01:06) in WELL HOME DESIGN NEWS, Sherri shares how to keep older loved ones safe in case of emergencies through natural disasters. (1:13:07) Me Time Monday Wellness Hack are 7 Brain Health Hacks that may help prevent Alzheimer's. And Sherri also extends a big THANK YOU to our podcast listeners for making us #6 on the Top 100 caregiving podcast list! Find out more at: caregivingclub.com/podcast/

This episode of StartUp Health NOW throws out the tech buzzwords and dives into the power of simple solutions. We meet two innovative founders in our Alzheimer's Moonshot Community who are using familiar technologies – the telephone and television – to tackle major healthcare challenges. First up, Paul Campbell, CEO & Co-founder of Moneta Health, explains how their evidence-based dementia care program utilizes an "old school meets new school" approach, using AI plus the humble landline to reach a wider audience and overcome tech barriers for patients with early-stage dementia and Alzheimer's. Then, Bill Uniowski, CEO & Co-founder of Zinnia, shares how his company is creating smart video content specifically designed for people with advanced dementia, offering a calming and therapeutic experience that reduces the need for medication and improves lives for both patients and caregivers. Join us for a refreshing look at how low-tech solutions can deliver high-impact healthcare. Innovating in Alzheimer's disease? Learn how you can join our Alzheimer's Moonshot. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox. Innovators: Health Transformer University fuels your health moonshot Funders: Become a Health Moonshot Champion

Sebastian Palmqvist, MD, PhD, and Wiesje van der Flier, PhD, cochairs of the 2024 Alzheimer's Association International Conference, speak with JAMA Medical News Lead Senior Staff Writer Rita Rubin, MA, about highlights from the annual meeting, including a blood test for Alzheimer disease, repurposing of a GLP-1 receptor agonist, and the possible brain risk from inhaling wildfire smoke. Related Content: A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke—Highlights From the AAIC

In this episode of the Wild Health Podcast, Dr.'s Carl Seger and Mike Stone dive into the exciting and controversial topic of GLP-1, particularly drugs like Ozempic and semaglutide. The conversation kicks off with the latest news about GLP-1 agonists, originally developed for diabetes but now being explored for a host of other potential benefits, including weight loss, cardiovascular health, and even the prevention of cognitive decline and Alzheimer's disease. The discussion also highlights the recent buzz around a study presented at the Alzheimer's Association International Conference, which suggests that GLP-1 agonists might help reduce the risk of Alzheimer's by reducing inflammation in the brain. Carl and Mike delve into the mechanisms of how these drugs might work beyond glucose control, exploring their potential anti-inflammatory effects and their implications for treating chronic diseases. They also discuss the ongoing phase 3 clinical trials that could provide more definitive answers. The episode wraps up with a focus on the importance of a holistic approach to health, emphasizing that while drugs like GLP-1 agonists could play a significant role, they are not a one-size-fits-all solution. They stress the need for maintaining a balanced diet, exercise, and body recomposition rather than merely focusing on weight loss. 

A new study suggests that particles found in wildfire smoke could increase the risk of getting dementia.一项新的研究表明，野火烟雾中的颗粒可能会增加患痴呆症的风险。Dementia is a progressive brain condition that causes thinking problems and other health issues. There are several forms of dementia, including Alzheimer's disease.痴呆是一种逐渐恶化的脑部疾病，会导致思维问题和其他健康问题。痴呆症有多种形式，包括阿尔茨海默病。Researchers reported the new findings about wildfire smoke at the recent Alzheimer's Association International Conference in Philadelphia, Pennsylvania.研究人员在最近于宾夕法尼亚州费城举行的阿尔茨海默病协会国际会议上报告了有关野火烟雾的新发现。The study centered on a substance called PM2.5. The substance is known as particulate matter, a mixture of small, solid particles and water droplets found in the air.这项研究的重点是一种称为PM2.5的物质。该物质被称为颗粒物，是空气中存在的小固体颗粒和水滴的混合物。PM2.5 particles are about 30 times smaller than a human hair. They can be breathed into the lungs and then move on to the bloodstream. Existing evidence shows this kind of pollution – from traffic, factories and fires – can cause or worsen heart disease. The new study finds it could also raise dementia risks.PM2.5颗粒约为人类头发丝的30分之一。它们可以被吸入肺部，然后进入血液。现有证据表明，这种来自交通、工厂和火灾的污染可以导致或加剧心脏病。新的研究发现，它还可能增加患痴呆症的风险。Claire Sexton is the director of scientific programs for the Alzheimer's Association. She said in a statement the study shows that increasing wildfires, especially in the American west, are “an increasing threat to brain health.” Sexton added that the findings demonstrate “the importance of enacting policies to prevent wildfires and investigating better methods to address them.”克莱尔·塞克斯顿是阿尔茨海默病协会科学项目的主任。她在一份声明中表示，这项研究表明，日益增加的野火，尤其是在美国西部，是“对脑部健康日益增加的威胁。”塞克斯顿补充说，这些发现证明了“制定防止野火政策和研究更好的应对方法的重要性。”Researchers from the University of Washington and the University of Pennsylvania carried out the study. They examined health records of 1.2 million older adults in Southern California between 2009 and 2019. The scientists used air quality monitoring and other data to estimate how much PM2.5 was released from wildfire smoke or other ways over three years.华盛顿大学和宾夕法尼亚大学的研究人员进行了这项研究。他们检查了2009年至2019年间南加州120万老年人的健康记录。科学家们使用空气质量监测和其他数据来估算三年内野火烟雾或其他方式释放的PM2.5的量。The study found the risk of being diagnosed with dementia increased about 21 percent for every 1 microgram increase in the concentration of wildfire particles. That compared with a 3 percent increased risk for every 3 microgram increase in non-wildfire particles.研究发现，每增加1微克的野火颗粒浓度，诊断为痴呆症的风险增加约21%。相比之下，每增加3微克的非野火颗粒，风险仅增加3%。It is not clear why this difference exists. But with wildfires increasing, this issue needs more study, said Alzheimer's Association chief science officer Maria Carrillo. She said it is especially important because the risk of Alzheimer's – the most common form of dementia – is higher for lower-income populations who may have a harder time avoiding unhealthy air.目前尚不清楚为什么会存在这种差异。但随着野火的增加，这个问题需要进一步研究，阿尔茨海默病协会首席科学官玛丽亚·卡里略表示。她说，这一点尤为重要，因为阿尔茨海默病——最常见的痴呆症形式——的风险在低收入人群中更高，这些人可能更难以避免不健康的空气。Carrillo noted that health warnings urge staying indoors when air quality is poor. But she added, “there are a lot of people who don't have the option to stay home or they work outside.”卡里略指出，健康警告建议在空气质量差的时候待在室内。但她补充说，“有很多人没有选择留在家中，或者他们在室外工作。”

The findings suggest the blood tests may be more helpful for general care doctors. They see many more cases of people with memory problems than specialists do. However, general care doctors have fewer diagnostic tools.研究结果表明，血液检测对全科医生可能更有帮助。他们接触到的记忆问题患者比专家多得多。然而，全科医生的诊断工具较少。In the study, patients who visited either a general care doctor or a specialist for memory problems got an early diagnosis using traditional exams. They gave blood for testing and got confirmatory spinal taps or brain scans. 在这项研究中，前往全科医生或专家就记忆问题就诊的患者，通过传统检查获得了早期诊断。他们进行了血液测试，并接受了确认性的脊髓穿刺或脑部扫描。 Blood testing is far more accurate, Lund University researchers reported recently at the Alzheimer's Association International Conference in Philadelphia. They said that the primary care doctors' first diagnosis was 61 percent accurate and the specialists' first diagnosis 73 percent. However, the blood test was 91 percent accurate, their study showed. The Journal of the American Medical Association published the study. 隆德大学的研究人员最近在费城的阿尔茨海默病协会国际会议上报告说，血液检测的准确性远远更高。他们表示，全科医生的初次诊断准确率为61%，而专家的初次诊断准确率为73%。然而，血液检测的准确率为91%，他们的研究显示。《美国医学会杂志》发布了这项研究。 Dr. John Hsiao of the National Institute on Aging said the new tests measure different biomarkers in different ways. 国家衰老研究所的约翰·萧博士表示，新检测以不同的方式测量不同的生物标志物。Doctors and researchers should only use blood tests proven to have a greater than 90 percent accuracy rate, said Alzheimer's Association chief science officer Maria Carrillo.阿尔茨海默病协会首席科学官玛丽亚·卡里略表示，医生和研究人员应该只使用准确率超过90%的血液检测。 Carrillo and Hsiao agreed that the blood tests most likely to provide that accuracy measure what is called p-tau217. Schindler helped lead an unusual direct comparison of several kinds of blood tests that came to the same finding. The Foundation for the National Institutes of Health financed the work. 卡里略和萧博士一致认为，最有可能提供这种准确性的血液检测是测量所谓的p-tau217。辛德勒帮助领导了一项不寻常的直接比较几种血液检测的工作，得出了相同的结论。国家卫生研究院基金会资助了这项工作。 That kind of test measures a form of tau that correlates with how much plaque buildup someone has, Schindler explained. A high level signals a strong likelihood the person has Alzheimer's. A low level strongly suggests Alzheimer's is not the cause of a patient's thinking problems. 这种测试测量一种tau蛋白形式，这种形式与个人的淀粉样斑块积累量相关，辛德勒解释说。高水平表明该人患阿尔茨海默病的可能性很大。低水平则强烈暗示阿尔茨海默病不是导致患者思维问题的原因。 Several companies are developing p-tau217 tests. 几家公司正在开发p-tau217测试。 In the United States, only doctors can order the blood tests from labs. The Alzheimer's Association is working on policy suggestions and several companies plan to seek FDA approval, which would clarify correct use. 在美国，只有医生可以从实验室订购血液检测。阿尔茨海默病协会正在制定政策建议，几家公司计划申请FDA批准，以明确正确使用方法。 For now, Carrillo said doctors should use blood testing only in people with memory problems, after checking the accuracy of the kind they order. 目前，卡里略表示，医生应仅在检查了所订购血液检测的准确性后，对记忆问题患者使用血液检测。 Especially for primary care physicians, “it really has great potential to help them in sorting out who to give a reassuring message and who to send on to memory specialists,” said Dr. Sebastian Palmqvist of Lund University. Palmqvist led the Swedish study with Lund's Dr. Oskar Hansson. 隆德大学的塞巴斯蒂安·帕尔姆奎斯特博士表示，对于全科医生来说，“这确实有很大的潜力，帮助他们判断谁需要安抚性信息，谁需要转诊给记忆专家。”帕尔姆奎斯特博士与隆德大学的奥斯卡·汉松博士共同领导了这项瑞典研究。

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast, recorded live from the Alzheimer's Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN's ongoing efforts to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell's latest podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio's recent Phase 2/3 Alzheimer's study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio's strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson's and Alzheimer's diseases. “Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer's patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer's research, underscores the importance of our work and the promise it holds for patients.” Join IBN's Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio's recent achievements, the next steps for buntanetap, and the company's future goals. To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com. The latest installment of The Bell2Bell Podcast continues to reinforce IBN's commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN's achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast, recorded live from the Alzheimer's Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN's ongoing efforts to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell's latest podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio's recent Phase 2/3 Alzheimer's study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio's strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson's and Alzheimer's diseases. “Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer's patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer's research, underscores the importance of our work and the promise it holds for patients.” Join IBN's Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio's recent achievements, the next steps for buntanetap, and the company's future goals. To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com. The latest installment of The Bell2Bell Podcast continues to reinforce IBN's commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN's achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The biotech industry is experiencing significant growth, with drugmakers in the U.S. and Europe raising $6.8 billion in venture capital funding in the first three months of the year. This trendline explores the evolving biotech market and highlights hotspots of startup activity. Stories included focus on an unorthodox investment firm supporting biotech's 'infrastructure', the rise in private biotech funding, and insights from biotech landlord Alexandria on research clusters and the sector's recovery.A study presented at the Alzheimer's Association International Conference showed that Novo Nordisk's GLP-1 drug liraglutide may slow cognitive decline in Alzheimer's patients by 18% compared to placebo over one year of treatment. Additionally, Novo's diabetes drug Ozempic was found to be linked to a lower risk for tobacco use disorder. Pfizer and Merck reported strong second-quarter earnings exceeding Wall Street expectations. Novo Nordisk's Ozempic was also found to potentially help diabetics quit smoking according to new research. Other news includes AstraZeneca's Calquence achieving positive results in a Phase III trial for CLL and Ventyx ending development of a Tyk2 inhibitor after a Phase II flop in Crohn's disease.Pfizer has decided to quit its Duchenne gene therapy program, resulting in the termination of 150 staff members. Incyte has also trimmed its cancer drug pipeline by discontinuing the development of five experimental treatments. The biotech market is seeing an increase in M&A activity, with companies like Boehringer making deals to add to their cancer drug pipeline. Overall, the industry is evolving with a focus on efficiency, effectiveness, and ethical innovation in clinical research.Sanofi's recent record sales quarter for its immunology drug Dupixent has boosted the company's confidence in its long-term strategy, following a previous dip in share value due to growth target adjustments. The company's spinoff of its consumer unit Opella is part of a trend among big pharma companies to focus on biopharma futures. Sanofi's Dupixent, with an expanding list of indications, is showing long-term value for the company and has the potential to become one of the best-selling drugs in the world by the end of the decade.Cleveland Clinic has appointed its first Chief AI Officer, Ben Shahshahani, to lead the health system's AI strategy, focusing on managing safety, ethics, and data security concerns. Healthcare organizations are facing obstacles in increasing patient response rates through phone communication. Healthcare Dive provides insights and news for healthcare leaders, covering various topics such as health IT, policy & regulation, insurance, digital health, payer-provider partnerships, and value-based care.GSK has partnered with Flagship to help find new drugs and vaccines, similar to recent alliances with Pfizer and Novo Nordisk. Boehringer has acquired startup Nerio for up to $1.3 billion to expand its cancer drug pipeline. Autobahn raised $100 million for neuropsych drugs, while a startup led by former J&J executives, Third Arc Bio, raised $165 million for cancer and immune disease drugs. The competitive market for obesity drugs is growing, with analysts expecting significant revenue from drugs like Novo's and Eli Lilly's.Biopharma Dive provides in-depth coverage of industry news and trends, covering topics from clinical trials to drug pricing and research partnerships.Support the Show.

Send us a Text Message.The Davos Alzheimer's Collaborative ( DAC - https://www.davosalzheimerscollaborative.org/ ) is a pioneering worldwide initiative to cure Alzheimer's disease and dementia, seeking to mirror the success of global efforts against infectious diseases such as HIV/AIDS, Covid, and Malaria. Absent effective action at scale around the world, by 2050, more than 150 million families and half a billion people will be personally impacted by Alzheimer's, creating a social, financial, economic, and global security disaster of historic proportions. DAC was launched in Davos in 2021 by the World Economic Forum and the Global CEO Initiative on Alzheimer's Disease. Dr. Tim MacLeod is the Director of the Systems Preparedness workstream of the Davos Alzheimer's Collaborative (DAC) where he executes on a mission to facilitate the implementation of national, regional, and global commitments to provide access to future innovations in treatment, diagnosis, and care. Drawing on his background in implementation science and innovation consulting, Dr. MacLeod guides the development, execution, and dissemination of multi-site, real-world implementation studies that generate evidence about the facilitators and barriers to adopting and scaling novel technology in the ADRD space. Before joining DAC, Dr. MacLeod led the award-winning human-centered design studio Bridgeable as Managing Director, where he worked with Fortune 500 companies in the financial service and health spaces on significant innovation initiatives. Dr. MacLeod holds a Ph.D. in community psychology and has published widely on health innovation and implementation science. His research with the Mental Health Commission of Canada's At Home/Chez Soi team scaled the Housing First model from 5 pilot sites to over 20 cities nationally through multi-level policy change. Dr. Vaibhav Narayan is Executive Vice President at the Davos Alzheimer's Collaborative (DAC), which he joined after 13+ years at Johnson & Johnson (J&J) where he was Vice President of Digital Health Innovation and Head of Data Science for Neuroscience R&D. At J&J, Dr.  Narayan created and led programs that utilized multi-modal data from ‘genomics to digital' to understand disease subtypes and develop AI/ML driven digital health solutions for prevention, early detection, disease course monitoring and prediction in Alzheimer's and neuropsychiatric diseases. Dr. Narayan also previously served as Head, Discovery Informatics, Eli Lilly and Company, and as Director, Computational Sciences, Celera Genomics.  He also currently serves a role as Chief Industry Officer, UK Mental Health Mission, University of Oxford.Dr. Narayan obtained a PhD from Yale University in computational biology and an Executive MBA from Kellogg School of Management, Northwestern University.Important Episode Links The Davos Alzheimer's Collaborative Healthcare System Preparedness(DAC-SP) Early Detection Blueprint - https://www.dacblueprint.org/Alzheimer's Association International Conference 2024 - https://aaic.alz.org/#Alzheimers #Dementia #Davos #Neurology #Neuroscience #HealthyAging #BrainHealth  #TimMacLeod  #VaibhavNarayan #DavosAlzheimersCollaborative #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the Show.

Welcome to the fifth season of the ISTAART PIA Relay Podcast, brought to you by Dementia Researcher. This series features members of ISTAART, engaging in insightful interviews about groundbreaking dementia research, and the work of the ISTAART Professional Interest Areas (PIA) they represent. As we build up to the Alzheimer's Association International Conference in Philadelphia, join us for daily episodes that showcase the remarkable work being done in various research fields. -- In this episode, Professor Arlene Astell interviews Caitlyn Fastenau, a PhD candidate in Integrated Biomedical Sciences focusing on the Biology of Ageing. Caitlyn shares her journey into dementia research, driven by personal experiences and a passion for understanding neurodegenerative diseases. Her research explores the role of immune cells, particularly microglia, in Alzheimer's disease, using advanced techniques like single-cell RNA sequencing. Caitlyn discusses the her work, the importance of diversity in research, highlighting efforts to include underrepresented communities in dementia studies. She also talks about the significance of translational research and the potential non-pharmacological interventions that could reduce the risk of neurodegenerative diseases. Tune in to learn more about the Immunity and Neurodegeneration PIA, what they have planned for AAIC and the latest hot topics in the field, and the collaborative environment that ISTAART provides for researchers at all levels. PS. Don't miss Caitlyn's presentation at the AAIC and her insights on leveraging student engagement in scientific societies. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org -- You can also enjoy this show as a video on our YouTube Channel at: https://youtu.be/dddOpDsuwlM -- Find more information on our guests, and a full transcript of this podcast on our website at: www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Six years following the start of Dementia Matters in October 2017, the podcast team turns the tables on our host, Dr. Nathaniel Chin. Producers Amy Lambright Murphy and Caoilfhinn Rauwerdink talk with Dr. Chin about how the podcast got started, the brain health tips he incorporates into his own life, how he envisions the field of Alzheimer's disease research advancing in the next five years and other personal insights from the person behind the podcast. Guest: Nathaniel Chin, MD, geriatrician, medical director, Wisconsin Alzheimer's Disease Research Center, Wisconsin Registry for Alzheimer's Prevention, host, Dementia Matters Show Notes Visit our “Prevention” webpage for more on the brain health tips mentioned at 7:07. Listen to our episode, “Highlights from the 2023 Alzheimer's Association International Conference,” referenced at 10:49, on our website, Spotify, Apple Podcasts, or wherever you get your podcasts. Learn more about the importance of a healthy diet, mentioned at 8:25, by watching, “Take Care of Your MIND: Reviewing the MIND Diet for Healthy Brain Aging,” on our YouTube channel. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

The 2023 Alzheimer's Association International Conference (AAIC) in Amsterdam brought together the world's leading scientists, clinical researchers, early career investigators, caregiving researchers and more to discuss the latest findings and advancements in dementia science. Dr. Percy Griffin joins the podcast to share key highlights from the conference. He discusses the use of CRISPR technology in Alzheimer's research, the significance of defining Alzheimer's by its biology rather than its symptoms and how the field is moving toward a precision medicine approach.  Guest: Percy Griffin, PhD, director of scientific engagement, Alzheimer's Association Show Notes Learn more about the Wisconsin Alzheimer's Disease Research Center's Fall Community Conversation on our website, and watch the livestream on our YouTube page. AAIC is the world's largest forum dedicated to advancing dementia research. Find more highlights from the conference, including on-demand content that is available to watch through September 20, 2023, at 11:59 p.m. CT, on the AAIC website. Find news highlights on CRISPR technology, county-level prevalence data on Alzheimer's, the ACHIEVE study and more mentioned by Dr. Griffin on the AAIC website. Listen to our AAIC 2022 highlights episode with Dr. Griffin, mentioned at 1:15, on our website, Spotify, Apple Podcasts, YouTube, or wherever you listen. Learn more about Dr. Griffin in his bio on the Alzheimer's Association's website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

Dementia affects 55 million people worldwide, and its most common form, Alzheimer's, accounts for about 70 percent of all cases.At the Alzheimer's Association International Conference, the largest congress advocating dementia science, held in Amsterdam this month, a pharmaceutical company disclosed details of its trials of a new drug: donanemab.The American company, Eli Lilly, expects the United States Food and Drug Administration (FDA) to decide by the end of 2023 whether to approve what it is calling a "breakthrough" drug.But is this medication the best way forward? Or does it just supply cash flow for the pharmaceutical industry?Leading dementia scientists Edo Richard and Craig Ritchie talk to Al Jazeera.Subscribe to our channel http://bit.ly/AJSubscribeFollow us on Twitter https://twitter.com/AJEnglishFind us on Facebook https://www.facebook.com/aljazeeraCheck our website: http://www.aljazeera.com/Check out our Instagram page: https://www.instagram.com/aljazeeraenglish/@AljazeeraEnglish#Aljazeeraenglish#News

Another experimental Alzheimer's drug has been shown to slow patients' worsening conditions, researchers reported Monday. The American drug company Eli Lilly said it is seeking U.S. Food and Drug Administration (FDA) approval for the drug donanemab. If approved, it would be the second Alzheimer's treatment for delaying the disease. Alzheimer's affects the brain and causes memory loss and dementia. The FDA approved Leqembi, from Japanese drugmaker Eisai, earlier this month. “Finally there's some hope, right, that we can talk about,” Lilly's Dr. John Sims told reporters Monday at the Alzheimer's Association International Conference in Amsterdam, the Netherlands.研究人员周一报道称，另一种实验性阿尔茨海默病药物已被证明可以减缓患者病情的恶化。美国制药公司礼来公司表示，正在寻求美国食品和药物管理局（FDA）批准其药物 donanemab。 如果获得批准，这将是第二种延缓阿尔茨海默病的治疗方法。 阿尔茨海默病会影响大脑并导致记忆丧失和痴呆。FDA 本月早些时候批准了日本制药商卫材 (Eisai) 的 Leqembi。礼来公司的约翰·西姆斯博士周一在荷兰阿姆斯特丹举行的阿尔茨海默病协会国际会议上对记者说：“终于有一些希望了，对吧，我们可以讨论一下。”The drug does not cure the disease. Instead, it slows its progression by about four to seven months. But Sims noted that “it doesn't mean you can't have very meaningful treatments for patients.” Eli Lilly published the full results of its study of 1,700 patients in the Journal of the American Medical Association. It also presented its results at the Alzheimer's conference. Both donanemab and Leqembi are laboratory-made antibodies. The treatments are injected into the patients. The drugs target a protein buildup, called beta amyloid, in the brain of Alzheimer's patients. Both drugs come with serious safety concerns. Patients can experience brain swelling or bleeding. In the Lilly study, such side effects were linked to three deaths.该药物不能治愈该疾病。 相反，它会减慢其进展约四到七个月。 但西姆斯指出，“这并不意味着你不能为患者提供非常有意义的治疗。”礼来公司 (Eli Lilly) 在《美国医学会杂志》上发表了对 1,700 名患者进行的研究的完整结果。 它还在阿尔茨海默病会议上展示了其研究结果。donanemab 和 Leqembi 都是实验室制造的抗体。 将治疗药物注射到患者体内。 这些药物针对的是阿尔茨海默病患者大脑中一种称为β淀粉样蛋白的蛋白质积聚。这两种药物都存在严重的安全问题。 患者可能会出现脑肿胀或出血。 在礼来公司的研究中，此类副作用与三人死亡有关。Dr. Liana Apostolova was the study investigator. She is also a professor in Alzheimer's Disease research at Indiana University School of Medicine. She said, "These side effects should not be taken lightly." But she added that, in most cases, the effects were well controlled by monitoring with magnetic resonance imaging (MRI) or by stopping using the drug.Lilly's study included people ages 60 to 85 who were in the early stages of Alzheimer's. Half of the study subjects received a monthly injection of donanemab for up to 18 months. The other half received an inactive substance, called a placebo. Patients were also switched to inactive substances if enough amyloid cleared out. The study found that it happened to half of the patients within a year. Amyloid alone does not cause Alzheimer's. So researchers also studied the levels of tau, another protein that causes the disease in the brain. Patients with higher levels of tau are considered to be in the more advanced stages of Alzheimer's.Liana Apostolova 博士是该研究的调查员。 她还是印第安纳大学医学院阿尔茨海默病研究的教授。 她说：“这些副作用不应掉以轻心。” 但她补充说，在大多数情况下，通过磁共振成像（MRI）监测或停止使用药物可以很好地控制效果。礼来公司的研究对象是年龄在 60 岁至 85 岁之间、处于阿尔茨海默病早期阶段的人。 一半的研究对象每月注射多南单抗，持续长达 18 个月。 另一半则接受一种称为安慰剂的非活性物质。如果清除了足够的淀粉样蛋白，患者也会改用非活性物质。 研究发现，一半的患者在一年内发生了这种情况。淀粉样蛋白本身并不会导致阿尔茨海默病。 因此，研究人员还研究了 tau 蛋白的水平，tau 蛋白是另一种导致大脑疾病的蛋白质。 tau 水平较高的患者被认为处于阿尔茨海默病的晚期阶段。The results: both groups declined during the 18-month study but the drug appears to work better for patients in earlier stages of the disease. Those with low to medium tau levels saw a 35- percent slower decline. For high tau patients, donanemab slowed the disease progression by about 17 percent. Anne White is the president of neuroscience at Lilly. She said, "At the end of the trial, the average patient had been without drugs for seven months and yet they continued to benefit.” Scientists say that, while these drugs may mark a new era in Alzheimer's treatment, huge questions remain about which patients should try them. Questions also remain about how much benefit patients will really experience. The main safety concern is brain swelling or bleeding. These conditions often cause no symptoms but sometimes can be serious, even deadly.结果：在 18 个月的研究中，两组患者的病情均有所下降，但该药物似乎对疾病早期阶段的患者效果更好。 tau 水平低到中等的人的下降速度慢了 35%。 对于高 tau 蛋白患者，donanemab 将疾病进展速度减慢了约 17%。安妮·怀特 (Anne White) 是礼来公司神经科学总裁。 她说：“试验结束时，患者平均已经七个月没有服用药物，但他们仍然受益。”科学家表示，虽然这些药物可能标志着阿尔茨海默病治疗的新时代，但哪些患者应该尝试这些药物仍然存在巨大问题。 关于患者真正能得到多少好处仍然存在疑问。主要的安全问题是脑肿胀或出血。 这些情况通常不会引起任何症状，但有时可能很严重，甚至致命。Another concern is that more than 90 percent of the study's patients were white. That means there is little data on how effective the treatment could be for other populations, said Alzheimer's specialist Jennifer Manly of Columbia University. Lilly expects the FDA to decide by the end of this year whether to approve donanemab. The company is also seeking approval from other health agencies worldwide.另一个担忧是该研究中超过 90% 的患者是白人。 哥伦比亚大学阿尔茨海默病专家詹妮弗·曼利说，这意味着关于这种治疗对其他人群的有效性的数据很少。礼来公司预计 FDA 将在今年年底前决定是否批准 donanemab。 该公司还在寻求全球其他卫生机构的批准。

US pharmaceutical giant Eli Lilly will unveil the full results of its trials of the drug 'donanemab' - which is the second shown to slow progression of dementia. The results of the donanemab trial will be revealed at the Alzheimer's Association International Conference in Amsterdam, and the drug could be licenced as safe in the UK in as little as a year to 18 months. The NHS would then have to weigh up the cost effectiveness when it comes to who it can give the drug to. Today's Mishal Husain speaks to Hilary Evans, Chief Executive of Alzheimer's Research UK and Co-Chair of UK Government Dementia Mission, and Professor Sir John Hardy, Professor of Neurodegenerative Disease at UCL - who advised the pharmaceutical company Eli Lilly during the development of donanemab. Photo credit: Denis Balibouse, Reuters

This Week In Wellness two new large studies across two countries published in the BMJ have shown that ultra-processed foods were linked to an increased risk of heart disease, colo-rectal cancers in men and early death in both men and women whilst another study presented at the 2022 Alzheimer’s Association International Conference has shown that Listen In The post TWIW 168: Ultra-processed foods linked to cancer, cognitive decline and early death appeared first on The Wellness Couch.

AAIC Special Series Part 8: Closing out our special series spotlighting the 2022 Alzheimer's Association International Conference, Dr. Percy Griffin joins the podcast to discuss highlights from this year's event. Guest: Percy Griffin, PhD, director, scientific engagement, Alzheimer's Association Show Notes Find more highlights from the conference, including on-demand content that is available to watch through September 1, 2022 at 11:59p.m. PT , at the AAIC website. Learn more about Dr. Percy Griffin at his bio on the Alzheimer's Association website. Listen to our AAIC special series episode with Dr. Carl Hill, mentioned by Dr. Chin at 3:41, on our website, Spotify, Apple Podcasts, YouTube, or wherever you listen. Listen to our AAIC special series episode with Dr. Heather Snyder, mentioned by Dr. Chin at 18:22, on our website, Spotify, Apple Podcasts, YouTube, or wherever you listen Find the news highlights on diet, racism, preeclampsia, COVID-19, and more mentioned by Dr. Chin at the AAIC website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

New research from multiple studies – yet to be published – was highlighted at the Alzheimer's Association International Conference in San Diego, August. This hour on Where We Live, we discuss studies that show high blood pressure during pregnancy; consumption of highly processed foods; and the loss of smell and taste are all predictors of cognitive decline later on. We hear from an Alzheimer's patient and his caregiver wife about life before and after joining an Eli Lilly clinical trial. And later, we hear about new research on how experiencing discrimination and racism increases the risk of memory loss. According to the Alzheimer's Association, there are 6 million Americans living with Alzheimer's disease. In Connecticut, that number is 80,000. Nationally, two-thirds of women have Alzheimer's and two-thirds of women are caregivers for someone who has the disease. GUESTS:  Sandi and George Carlino: George has early stage Alzheimer's and is in an Eli Lilly clinical trial in New Haven. Dr. Amy Sanders: Medical Director of the Hartford HealthCare Memory Care Center, and a Medical Scientific Advisory Council member at the Alzheimer's Association, Connecticut Chapter. Dr. Carl Hill: Chief Diversity, Equity and Inclusion Officer, Alzheimer's Association. Support the show: http://wnpr.org/donateSee omnystudio.com/listener for privacy information.

Christy Kovel Director of Public Policy CT Alzheimer's Association.  Just returned from the Alzheimer's Association International Conference.

HEALTH NEWS   Hyaluranic acid, a naturally occurring compound, awakens stem cells to repair damaged muscle 'A banana a day': Starch supplement may reduce the risk of some hereditary cancers Running reduces risk of death regardless of duration, speed Eating processed foods is hurting your brain, study says: Even '2 cookies' can affect health Sharing memories with toddlers helps their well-being into adulthood What the Amish can teach us about health and happiness   Hyaluranic acid, a naturally occurring compound, awakens stem cells to repair damaged muscle University of Ottawa (Ontario), August 4 2022 A new study published in the journal Science reveals a unique form of cell communication that controls muscle repair. In damaged muscle, stem cells must work together with immune cells to complete the repair process, yet how these cells coordinate to ensure the efficient removal of dead tissue before making new muscle fibers has remained unknown. The scientists have now shown that a natural substance called hyaluronic acid, which is used in cosmetics and injections for osteoarthritis, is the key molecule that manages this fundamental interaction. "When muscles get damaged, it is important for immune cells to quickly enter the tissue and remove the damage before stem cellsbegin repair," said Dr. Jeffrey Dilworth, senior scientist at the University of Ottawa and senior author on the study. "Our study shows that muscle stem cells are primed to start repair right away, but the immune cells maintain the stem cells in a resting state while they finish the cleanup job. After about 40 hours, once the cleanup job is finished, an internal alarm goes off in the muscle stem cells that allows them to wake up and start repair." Dr. Dilworth and his team identified hyaluronic acid as the key ingredient in this internal alarm clock that tells muscle stem cells when to wake up. When muscle damage occurs, stem cells start producing and coating themselves with hyaluronic acid. Once the coating gets thick enough, it blocks the sleep signal from the immune cells and causes the muscle stem cells to wake up. "Interestingly, aging is associated with chronic inflammation, muscle weakness and a reduced ability of muscle stem cells to wake up and repair damage,. "If we could find a way to enhance hyaluronic acid production in the muscle stem cells of older people it might help with muscle repair." 'A banana a day': Starch supplement may reduce the risk of some hereditary cancers Universities of Newcastle and Leeds (UK), August 4, 2022 Resistant starches (RS) are carbohydrates that pass undigested through the small intestine and are digested, or fermented, in the large intestine. They are present in plant-based foods including beans, oats, breakfast cereals, rice, cooked and cooled pasta, peas, and slightly unripe bananas. RS forms part of dietary fiber, which is known to reduce the risk of colorectal cancer and many other non-communicable diseases. Researchers at Newcastle University and the University of Leeds in the United Kingdom found that a RS powder supplement may help prevent cancer in people with Lynch syndrome. Lynch syndrome, an inherited condition, predisposes people to colon cancer, gastric cancer, and several other cancers. The experts ran a multinational trial involving almost 1,000 people with Lynch syndrome. They gave the participants a 30g dose of RS for an average of two years. The supplementation did not affect colorectal cancers as expected. However, unexpectedly, its protective potential was most apparent in the upper digestive tract, where cancers are aggressive and not usually caught early.The  trial analyzed the long-term effects of aspirin and RS on cancer onset in patients with Lynch syndrome. The dose used was equivalent to eating one slightly unripe banana daily. Bananas at this stage resist breakdown in the small intestine, reaching the large intestine and feeding the microbiome there. They found no difference in the number of colorectal cancer cases. However, fewer participants receiving the supplement developed non-colorectal LS cancers compared to those taking the placebo.   Running reduces risk of death regardless of duration, speed Iowa State University,  July 29, 2022   Running 5 minutes daily can reduce risk of cardiovascular disease-related death   Running for only a few minutes a day or at slow speeds may significantly reduce a person's risk of death from cardiovascular disease compared to someone who does not run, according to a study published in the Journal of the American College of Cardiology.    Researchers studied 55,137 adults between the ages of 18 and 100 over a 15-year period to determine whether there is a relationship between running and longevity. In the study period, 3,413 participants died, including 1,217 whose deaths were related to cardiovascular disease. In this population, 24 percent of the participants reported running as part of their leisure-time exercise.    Compared with non-runners, the runners had a 30 percent lower risk of death from all causes and a 45 percent lower risk of death from heart disease or stroke. Runners on average lived three years longer compared to non-runners. Also, to reduce mortality risk at a population level from a public health perspective, the authors concluded that promoting running is as important as preventing smoking, obesity or hypertension. The benefits were the same no matter how long, far, frequently or fast participants reported running. Benefits were also the same regardless of sex, age, body mass index, health conditions, smoking status or alcohol use.   The study showed that participants who ran less than 51 minutes, fewer than 6 miles, slower than 6 miles per hour, or only one to two times per week had a lower risk of dying compared to those who did not run. Runners who ran less than an hour per week have the same mortality benefits compared to runners who ran more than three hours per week. Thus, it is possible that the more may not be the better in relation to running and longevity.      Eating processed foods is hurting your brain, study says: Even '2 cookies' can affect health Yale University, August 3, 2022 Although it's obvious that a diet of hot dogs and ice cream won't lead to a healthy physical life, new research illuminates how ultra-processed foods can also cause a significant decrease in brain function. Research presented at the Alzheimer's Association International Conference in San Diego outlined how foods such as instant noodles, sugary drinks and frozen meals all play a factor in a faster rate of cognitive decline. "Just 100 calories of processed foods can affect your physical health. So, that's two cookies." Research has linked ultra-processed food consumption to health problems like obesity, cardiovascular disease, diabetes and cancers.  That's because they cause inflammation, which can affect neurotransmitters in the brain. Processed foods also operate on a micro level with billions and billions of bacteria cells that (impair) functioning." The findings found that participants who were getting 20% or more of their daily calories from ultra-processed foods saw a far faster decline in cognitive performance over the span of six to 10 years versus people with diets containing few processed foods.   Sharing memories with toddlers helps their well-being into adulthood University of Otago (New Zealand), August 3 2022 How mothers share memories with their children during toddlerhood impacts mental health and well-being in early adulthood, a University of Otago study has shown. Researchers found 21-year-olds told more coherent stories about turning points in their lives if their mothers were taught new conversational techniques two decades earlier. These adults also reported fewer symptoms of depression and greater self-esteem compared to adults in the study whose mothers interacted with them as usual. The study, published in Journal of Research in Personality, is a long-term follow-up of a reminiscing intervention in which 115 mothers of toddlers were assigned to either a control group or taught to use elaborative reminiscing for a year. Elaborative reminiscing involves open, enriched, and responsive conversations with children about shared experiences of everyday events. This is the first study to show long-term benefits of mother-child reminiscing for emerging adult development.   What the Amish can teach us about health and happiness University of Tennessee, July 29, 2022  Often viewed as outcasts by mainstream society, the Amish may seem downright bizarre to the average American. Foregoing technological advancements that many of us would be lost without, the Amish have created a way of life that fosters a connection with the land and environment, while also cultivating an impressive sense of community. And they are healthy -- exceedingly so. The Amish rarely experience disorders like cancer or cardiovascular disease, seemingly able to bypass illness altogether. What's their secret?   One of the most striking aspects of the Amish is how they lead their lives, free from modern inventions like electricity, telephones, cars and the myriad of gadgets most of us consider so essential for our productivity and happiness. This high level of daily physical activity helps to keep their obesity rates low and cardiovascular health in top form.    "The Amish were able to show us just how far we've fallen in the last 150 years or so in terms of the amount of physical activity we typically perform. Their lifestyle indicates that physical activity played a critical role in keeping our ancestors fit and healthy."  One of the main contributors to stress is the speed at which we move, think and process. We are bombarded with sensory information at every turn.    Not so with the Amish. Their communities are based on patience and a slower way of being. Competition is frowned upon, while cooperation and harmony are respected. Social support is strong. Through traditional gender roles, each person has a valued part to play within the community.   The study published in Scientific Research discovered that mental health is enhanced by the structure of Amish society. Martial stability, mutual support, a secure parental base and care for the elderly were found to be contributing factors in cultivating happiness and contentment.   Moreover, the Amish tend to have low vaccination rates. Instead, they rely on clean living and a healthy diet of homegrown, organic produce, raw dairy and nourishing fats to keep immunity strong.

Videos: How the US Stole Central America (With Bananas) – Johnny Harris   HEALTH NEWS Black cardamom bioactives effective against lung cancer cells Soybean oil causes more obesity than coconut oil and fructose Why breast-fed premature infants have healthier guts than formula-fed ones Even simple exercise may help aging brain, study hintsSmall daily portion of Jarlsberg cheese may help to stave off bone thinning Body fat can send signals to brain, affecting stress response Black cardamom bioactives effective against lung cancer cells National University of Singapore, August 1, 2022 The main challenges associated with existing lung cancer drugs are severe side effects and drug resistance. There is hence a constant need to explore new molecules for improving the survival rate and quality of life of lung cancer patients. In Indian Ayurvedic medicine, black cardamom has been used in formulations to treat cancer and lung conditions. A team of researchers from the NUS Faculty of Science studied the scientific basis behind this traditional medicinal practice and provided evidence of the cytotoxic effect of black cardamom on lung cancer cells. The research highlighted the spice as a source of potent bioactives, such as cardamonin and alpinetin, which could be used in the treatment or prevention of lung cancer. The study is the first to report the association of black cardamom extract with oxidative stress induction in lung cancer cells, and compare the spice's effects on lung, breast and liver cancer cells. The findings could potentially lead to the discovery of safe and effective new bioactives which can prevent or cure cancer formation. The research was first published in the Journal of Ethnopharmacology. Black cardamom is typically used in Asian households in rice preparations, curries and stews either as a whole spice or in powdered form. The spice is also prescribed in Indian Ayurvedic medicine in powder form where it is used for conditions such as cough, lung congestion, pulmonary tuberculosis, and throat diseases.  In the NUS study, black cardamom fruits were powdered and sequentially extracted with five types of solvents, including organic solvents and water. This allowed the researchers to evaluate the best solvents to extract the most potent actives in the fruit. The various types of black cardamom extracts were then tested for their cytotoxicity against several types of cancer cells. These included cancer cells from the lung, liver and breast. Among the three types of cells, lung cancer cells were least likely to survive when tested with the black cardamom extracts. Soybean oil causes more obesity than coconut oil and fructose University of California at Riverside, July 22, 2022 A diet high in soybean oil causes more obesity and diabetes than a diet high in fructose, a sugar commonly found in soda and processed foods, according to a published paper by scientists at the University of California, Riverside. The scientists fed male mice a series of four diets that contained 40 percent fat, similar to what Americans currently consume. In one diet the researchers used coconut oil, which consists primarily of saturated fat. In the second diet about half of the coconut oil was replaced with soybean oil, which contains primarily polyunsaturated fats and is a main ingredient in vegetable oil. That diet corresponded with roughly the amount of soybean oil Americans currently consume. The other two diets had added fructose, comparable to the amount consumed by many Americans. All four diets contained the same number of calories and there was no significant difference in the amount of food eaten by the mice on the diets. Thus, the researchers were able to study the effects of the different oils and fructose in the context of a constant caloric intake. Compared to mice on the high coconut oil diet, mice on the high soybean oil diet showed increased weight gain, larger fat deposits, a fatty liver with signs of injury, diabetes and insulin resistance, all of which are part of the Metabolic Syndrome. Fructose in the diet had less severe metabolic effects than soybean oil although it did cause more negative effects in the kidney and a marked increase in prolapsed rectums, a symptom of inflammatory bowel disease (IBD), which like obesity is on the rise. The mice on the soybean oil-enriched diet gained almost 25 percent more weight than the mice on the coconut oil diet and 9 percent more weight than those on the fructose-enriched diet. And the mice on the fructose-enriched diet gained 12 percent more weight than those on a coconut oil rich diet. Soybean oil now accounts for 60 percent of edible oil consumed in the United States. That increase in soybean oil consumption mirrors the rise in obesity rates in the United States in recent decades. During the same time, fructose consumption in the United States significantly increased, from about 37 grams per day in 1977 to about 49 grams per day in 2004. The UC Riverside researchers also did a study with corn oil, which induced more obesity than coconut oil but not quite as much as soybean oil. They are currently doing tests with lard and olive oil. They have not tested canola oil or palm oil. Why breast-fed premature infants have healthier guts than formula-fed ones University of Maryland School of Medicine, August 2, 2022 Human breastmilk has long been considered “liquid gold” among clinicians treating premature infants in a newborn intensive care unit (NICU). Breastmilk-fed “preemies” are healthier, on average, than those fed formula. Why is that true, however, has remained a mystery. New research from the University of Maryland School of Medicine's (UMSOM) Institute for Genome Sciences (IGS), found it is not just the content of breastmilkthat makes the difference. It is also the way the babies digest it. The research, led by Bing Ma, Ph.D., Assistant Professor of Microbiology and Immunology at UMSOM and a researcher at IGS, discovered a strain of the Bifidobacterium breve bacteria or B. breve in the guts of breastfed babies who received higher volumes of breastmilk than their counterparts. Those preemies had better nutrient absorptionbecause they developed an intact intestinal wall one week after birth. B. breve was much less prevalent in both formula-fed babies and breastfed babies with “leaky gut.” Babies with leaky gut do not develop a barrier to protect against bacteria and digested food from getting into the bloodstream. For the first time, the team also found that the way B. breve metabolizes breastmilk keeps breastfed babies healthier and allows them to gain weight by strengthening their underdeveloped intestinal barrier. An immature or “leaky” gut can lead to necrotizing enterocolitis (NEC), which is the third leading cause of newborn death in United States and worldwide. In fact, NEC impacts up to 10 percent of premature babies with a devastating mortality rate as high as 50 percent. At the most basic level, the gut microbiome in these breastfed preemies with more B. breve metabolizes carbohydrates differently than it does formula. The researchers say they hypothesize that this process of metabolism then strengthens and matures the intestinal barrier faster, protecting fragile newborns from disease. Even simple exercise may help aging brain, study hints Wake Forest School of Medicine, August 1, 2022 New research hints that even a simple exercise routine just might help older Americans with mild memory problems. Researchers recruited about 300 sedentary older adults with hard-to-spot memory changes called mild cognitive impairment or MCI—a condition that's sometimes, but not always, a precursor to Alzheimer's. Half were assigned aerobic exercises and the rest stretching-and-balance moves that only modestly raised their heart rate. After a year, cognitive testing showed overall neither group had worsened, said lead researcher Laura Baker, a neuroscientist at Wake Forest School of Medicine. Nor did brain scans show the shrinkage that accompanies worsening memory problems, she said. By comparison, similar MCI patients in another long-term study of brain health—but without exercise—experienced significant cognitive decline over a year. But the results suggest “this is doable for everybody”—not just seniors healthy enough to work up a hard sweat, said Baker, who presented the data Tuesday at the Alzheimer's Association International Conference. “Exercise needs to be part of the prevention strategies” for at-risk seniors. Small daily portion of Jarlsberg cheese may help to stave off bone thinning Norwegian Research Council, August 2, 2022 A small (57 g) daily portion of Jarlsberg cheese may help to stave off bone thinning (osteopenia/osteoporosis) without boosting harmful low density cholesterol, suggest the results of a small comparative clinical trial, published in the open access journal BMJ Nutrition Prevention & Health. The effects seem to be specific to this type of cheese, the findings indicate. Jarlsberg is a mild and semi-soft, nutty-flavored cheese made from cow's milk, with regular holes. It originates from Jarlsberg in eastern Norway. Previous research indicates that it may help boost levels of osteocalcin, a hormone that is associated with strong bones and teeth, but it's not clear if this effect is specific to Jarlsberg or any type of cheese. In a bid to find out, the researchers studied 66 healthy women (average age 33; average BMI of 24) who were randomly allocated to adding either a daily 57 g portion of Jarlsberg (41) or 50 g of Camembert cheese (25) to their diet for 6 weeks.  At the end of this period, the group eating Camembert was switched to Jarlsberg for another six weeks.  Jarlsberg and Camembert have similar fat and protein contents, but unlike Camembert, Jarlsberg is rich in vitamin K2, also known as menaquinone (MK), of which there are several varieties. Every six weeks blood samples were taken from all the participants to check for key proteins, osteocalcin, and a peptide (PINP) involved in bone turnover. Vitamin K2 and blood fat levels were also measured. Blood sample analysis showed that the key biochemical markers of bone turnover, including osteocalcin, and vitamin K2 increased significantly after 6 weeks in the Jarlsberg group.  Glycated hemoglobin (HbA1c)—-the amount of glucose stuck in red blood cells—fell significantly (by 3%) in the Jarlsberg group, while it rose sharply (by 2%) in those eating Camembert. But after switching to Jarlsberg HbA1c fell significantly in this group too. Calcium and magnesium fell significantly in the Jarlsberg group but remained unchanged in the Camembert group. After switching cheese, calcium levels dropped in this group too, possibly reflecting increased uptake of these key minerals in bone formation, say the researchers.  “Daily Jarlsberg cheese consumption has a positive effect on osteocalcin, other [markers of bone turnover], glycated hemoglobin and lipids,” write the researchers, concluding that the effects are specific to this cheese. Body fat can send signals to brain, affecting stress response University of Florida, July 23, 2022 The brain's effect on other parts of the body has been well established. Now, a group that includes two University of Florida researchers has found that it's a two-way street: Body fat can send a signal that affects the way the brain deals with stress and metabolism. While the exact nature of those signals remains a mystery, researchers say simply knowing such a pathway exists and learning more about it could help break a vicious cycle: Stress causes a desire to eat more, which can lead to obesity. And too much extra fat can impair the body's ability to send a signal to the brain to shut off the stress response. The findings are important and unique because they show that it's not simply the brain that drives the way the body responds to stress, said James Herman, Ph.D., a co-author of the paper and a professor in the department of psychiatry and behavioral neuroscience at the University of Cincinnati,. “It moved our understanding of stress control to include other parts of the body. Before this, everyone thought that the regulation of stress was mainly due to the brain. It's not just in the brain. This study suggests that stress regulation occurs on a much larger scale, including body systems controlling metabolism, such as fat,” Herman said. Researchers found that a glucocorticoid receptor in fat tissue can affect the way the brain controls stress and metabolism. Initially, such signals from the receptor can be lifesavers, directing the brain to regulate its energy balance and influencing stress responses in a beneficial way.

AAIC Special Series Part 1: To kick off our month-long special series previewing the 2022 Alzheimer's Association International Conference, or AAIC, we've invited  Claire Sexton, senior director of the Alzheimer's Association's scientific programs, to join us to discuss the goals of AAIC, how the pandemic impacted the influential conference, and what she's looking forward to at this year's event. Guest: Claire Sexton, DPhil, senior director of scientific programs and outreach, Alzheimer's Association Show Notes The AAIC is the world's largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Claire Sexton on the Alzheimer's Association website. Connect with us Find transcripts and more at our website. Email Dementia Matters at dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

Intro - 0:00Tune called Planxty Sir Festus Burke | Randal Bays/fiddle, Chris Smith/tenor banjo, Roger Landes/bouzouki | composition by Turlough O'Carolan, from the album “Coyote Banjo” by Chris SmithPart I, Meet Interim Dean Genevieve Durham DeCesaro - 01:10Part II, The Role of Dance in Both the Program & the Community - 12:38Part III, How to Learn from Our Body - 15:31Part IV, Music & Dance Coexist - 22:35Part V, Making Higher Education Inclusive - 30:00Part VI, Live Performances & Leadership Post-COVID - 39:55Part VI, Engaging with Students & Cultural Traditions in an Ethical Way -  44:28Part VII, What is Vernacular Dance & Why Does It Matter? - 50:15Outro - 54:04Planxty Sir Festus Burke BIO:  Prior to her appointment as Interim Dean, Professor of Dance Genevieve Durham DeCesaro served Texas Tech University as Vice Provost for Academic Affairs since 2014. She joined the Provost's staff after serving as Head of Dance since 2004 and as Associate Chair of the Department of Theatre and Dance since 2008. Her choreography has been commissioned and performed across the country, with notable presentations at Virginia Tech, Spelman College, and the John F. Kennedy Center for the Performing Arts in Washington, D.C.More recently, her artistic and scholarly research agenda has foregrounded perceptions of the human condition as understood and expressed through movement and other types of performance. Her work in this area, including the 2016 monograph Ordinary Wars: Doing Transdisciplinary Research (with Dr. Elizabeth Sharp) has been featured nationally and internationally, with key presentations at the Alzheimer's Association International Conference, Liverpool John Moores University, and the annual convention of the American Psychological Association. Interim Dean Durham DeCesaro currently serves as the Vice President for Regional Planning for the American College Dance Association and is a Visiting Evaluator for the National Association of Schools of Dance.Somatic Authority and the Myth of the Ideal Body in Dance Education Full Playlist for EP 28VVMC: Friends & Voices, a Collaborative Playlist VVMC Book ClubVoices from the Vernacular Music Center

We're still reeling from our first in-person conference post COVID. It was great to spend time among so many great and like-minded people at the Vacation Rental Managers Association International Conference in San Antonio, Texas. Listen for a rundown of our time there, from tips on how to get what you want out of people more effectively to how to handle negative reviews. To learn more, and for the complete show notes, visit: https://thanksforvisiting.me/ (thanksforvisiting.me) Resources: https://www.rentresponsibly.org (Rent Responsibly) https://www.breezeway.io (Breezeway) https://hostgpo.com (HostGPO) Visit https://www.thanksforvisiting.me/workshop (thanksforvisiting.me/workshop) to watch our Hosting Business Mastery Method workshop! #STRShareSunday: @mountainlakebungalow Thanks for Visiting is a production of http://crate.media (Crate Media)

Hideki Garren MD Ph.D. is the Chief Medical Officer at Prothena with a mission to advance the pipeline of candidates for neurodegenerative and protein amyloid diseases, including Alzheimer's and Parkinson's.  We talk about the recent FDA approval of aducanumab and its impact on research. Hideki says, "As we've shown at the AAIC, the Alzheimer's Association International Conference last week in Denver, we highlighted two out of three of our Alzheimer's disease potential treatments. One of them is PRX012, which is our anti-Aβ antibody. The second one that we showed there was a dual, Aβ-tau vaccine. And then thirdly, we have an anti-tau antibody, which is being developed. It was not shown at the AAIC, but we're also developing that. So these three molecules we're developing for Alzheimer's disease. And this momentum has really applied to us as well." #Prothena #Alzheimers #aduhelm #ProteinAmyloidDiseases #NeurodegenerativeDiseases #Vaccines #AAIC21 Prothena.com Listen to the podcast here

Hideki Garren MD Ph.D. is the Chief Medical Officer at Prothena with a mission to advance the pipeline of candidates for neurodegenerative and protein amyloid diseases, including Alzheimer's and Parkinson's.  We talk about the recent FDA approval of aducanumab and its impact on research. Hideki says, "As we've shown at the AAIC, the Alzheimer's Association International Conference last week in Denver, we highlighted two out of three of our Alzheimer's disease potential treatments. One of them is PRX012, which is our anti-Aβ antibody. The second one that we showed there was a dual, Aβ-tau vaccine. And then thirdly, we have an anti-tau antibody, which is being developed. It was not shown at the AAIC, but we're also developing that. So these three molecules we're developing for Alzheimer's disease. And this momentum has really applied to us as well." #Prothena #Alzheimers #aduhelm #ProteinAmyloidDiseases #NeurodegenerativeDiseases #Vaccines #AAIC21 Prothena.com Download the transcript here

Dr. Dayan Goodenowe joins Julie Gregory to discuss his new book, “Breaking Alzheimer's: A 15 Year Crusade to Expose the Cause and Deliver the Cure.” He talks about how his research lead him to plasmalogens and how they relate to neurological health. He explains what goes wrong biochemically as dementia develops and highlights age-related diminishing plasmalogen levels as a major driver of disease. He outlines his research showing that ApoE4 carriers may require more plasmalogens to maintain cognition, and he identifies tests and supplements to support plasmalogen levels. Finally, they discuss the unprecedented results of Dr. Goodenowe's newly completed clinical trial that he just reported on at the Alzheimer's Association International Conference.

This week, the CDC confirms a fatal case of melioidosis in Georgia; Moderna says its vaccine is 93% effective at 6 months; a survey shows patients prefer that physicians wear white coats; and more. Read the full coverage here: CDC confirms fatal case of melioidosis in Georgia, links it to previous US cases Moderna COVID-19 vaccine 93% effective, ‘durable' at 6 months, company says Casual attire is becoming more popular among physicians, but patients prefer white coats Modified Mediterranean-ketogenic diet may reduce cognitive decline Coexistence of bronchiectasis with asthma, chronic rhinosinusitis common References: Kawas MI, et al. Modified Mediterranean Ketogenic diet resolves default node network connectivity differences between adults with normal and impaired cognition: A pilot study. Presented at: Alzheimer's Association International Conference; July 26-30, 2021 (virtual meeting). Press Release. Press Release. Sheng H, et al. BMC Pulm Med. 2021;doi:10.1186/s12890-021-01575-7. Xun H, et al. JAMA Netw Open. 2021;doi:10.1001/jamanetworkopen.2021.17779.

The Alzheimer's Association International Conference took place in Denver this year. Today on the show, NPR science correspondent Jon Hamilton talks to Maddie Sofia about what he learned at the conference, the latest on the controversial new drug Aduhelm, and the potential links between COVID and Alzheimer's. You can follow more of Jon's reporting by clicking this link.Email the show at ShortWave@NPR.org.

As researchers from more than 110 countries gathered for the Alzheimer's Association International Conference, new data estimate the number of people with dementia globally will triple to more than 152 million by 2050.In this episode, BioWorld Staff Writer Lee Landenberger spoke with Howard Fillit, founding executive director and chief science officer at the Alzheimer's Drug Discovery Foundation, which was created to accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease. The geriatrician, neuroscientist and Mount Sinai School of Medicine professor has led the foundation since it was formed in 1998. He's seen a lot of change in the R&D of dementia treatments and shared his insights about the importance of biomarkers, the controversy surrounding Biogen Inc.'s recently approved Aduhelm (aducanumab) and the impact of financial investments that drive the development of these therapies compared to other indications. See acast.com/privacy for privacy and opt-out information.

La demenza sarà un grave problema di Sanità Pubblica nei prossimi anni, in relazione all’incremento delle diagnosi di demenza nella popolazione, all’aumento dell’età media della gente, al problema della sovrapopolazione ed alla oggettiva mancanza di risorse per gestire questi pazienti molto difficili.Per questa ragione vi voglio proporre una strategia per affrontare i 12 Fattori di Rischio per la Demenza che sono stati identificati da un bellissimo report fatto dalla Lancet Commission on Dementia Prevention, Intervention, and Care che è stato presentato all’Alzheimer’s Association International Conference del 2020. Eccovi il link al documanto completo:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30367-6/fulltextSpero che questo articolo sia utile a consapevolizzare le persone sull'importanza di una lotta personale alla DEMENZA tramite il raggiungimento di uno stile di vita più sano ed all'eliminazione di vari fattori di rischio. #demenza #salutementaleISCRIVETEVI AL MIO CANALE ► https://bit.ly/2zGIJorVi interessano la Psichiatria e le Neuroscienze? Bene, allora iscrivetevi a questo podcast, al mio canale YouTube e seguitemi sul web tramite il mio blog https://www.valeriorosso.comInoltre andate su Amazon a dare un’occhiata ai miei libri:“Psicobiotica” - Un nuovo modo di intendere il rapporto tra la Mente ed il Corpo….andate su: https://amzn.to/2IZwjhm“Psichiatria Rock” - 50 pensieri off line dal mio blog….andate su: https://amzn.to/2IVKKmJIl Dr. Valerio Rosso, su questo canale YouTube, si dedica a produrre delle brevi lezioni di psichiatria rivolte ai pazienti, agli operatori della salute mentale, a famigliari di pazienti ed a chiunque sia interessato alla psichiatria ed alle neuroscienze.

La demenza sarà un grave problema di Sanità Pubblica nei prossimi anni, in relazione all’incremento delle diagnosi di demenza nella popolazione, all’aumento dell’età media della gente, al problema della sovrapopolazione ed alla oggettiva mancanza di risorse per gestire questi pazienti molto difficili.Per questa ragione vi voglio proporre una strategia per affrontare i 12 Fattori di Rischio per la Demenza che sono stati identificati da un bellissimo report fatto dalla Lancet Commission on Dementia Prevention, Intervention, and Care che è stato presentato all’Alzheimer’s Association International Conference del 2020. Eccovi il link al documanto completo:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30367-6/fulltextSpero che questo articolo sia utile a consapevolizzare le persone sull'importanza di una lotta personale alla DEMENZA tramite il raggiungimento di uno stile di vita più sano ed all'eliminazione di vari fattori di rischio. #demenza #salutementaleISCRIVETEVI AL MIO CANALE ► https://bit.ly/2zGIJorVi interessano la Psichiatria e le Neuroscienze? Bene, allora iscrivetevi a questo podcast, al mio canale YouTube e seguitemi sul web tramite il mio blog https://www.valeriorosso.comInoltre andate su Amazon a dare un’occhiata ai miei libri:“Psicobiotica” - Un nuovo modo di intendere il rapporto tra la Mente ed il Corpo….andate su: https://amzn.to/2IZwjhm“Psichiatria Rock” - 50 pensieri off line dal mio blog….andate su: https://amzn.to/2IVKKmJIl Dr. Valerio Rosso, su questo canale YouTube, si dedica a produrre delle brevi lezioni di psichiatria rivolte ai pazienti, agli operatori della salute mentale, a famigliari di pazienti ed a chiunque sia interessato alla psichiatria ed alle neuroscienze.

Dr. RJ Tesi, CEO of INmune Bio, Inc., a clinical stage immuno-oncology company targeting neuroinflammation to fight brain disease, discusses positive data presented at The Alzheimer’s Association International Conference® 2020 from its XPro1595 Phase 1b Clinical Trial in Alzheimer's disease patients. These data showed the anti-inflammatory effects of XPro1595 on neuroinflammation in the arcuate fasciculus (AF) are impressive and consistent with preclinical data.

A simple blood test to diagnose Alzheimer's disease -- on the wish list of many doctors, researchers and patients -- may be closer to becoming a reality, according to the results of studies presented virtually this week during the Alzheimer's Association International Conference 2020.In a study presented Tuesday at the conference and published in JAMA, a blood test to detect the tau protein, one of the hallmark signs of Alzheimer's, was as accurate as a spinal tap or a positron emission tomography (PET) scan, which are the current gold standards of diagnosis while a person is living.The test could also differentiate between different types of cognitive dementia and even flag early signs of Alzheimer's. While more research is required and such a test is likely still years away from being available, experts say the results are encouraging."This research represents an exciting step towards developing a blood test that could help identify Alzheimer's disease by focusing on specific sub-types of tau, one of the key proteins that becomes abnormal as part of the Alzheimer's disease changes in the brain," said Clive Ballard, professor of age-related disease at the University of Exeter Medical School, in the UK, who was not involved in the study."A reliable blood test for Alzheimer's disease would be a huge boost for dementia research, allowing scientists to test treatments at a much earlier stage which in turn could lead to a breakthrough for those living with dementia," said Dr. Rosa Sancho, head of research at Alzheimer's Research UK, who was also not involved in the study.Looking for a mutant proteinIn a three-part study, researchers from the United States and Sweden measured an abnormal version of the tau protein called p-tau217 and found more of that modified tau in the blood of people with Alzheimer's disease than in healthy participants.How does tau get into blood? It appears to cross the blood-brain barrier."Tau protein is modified and clumps abnormally in the brains of people with Alzheimer's disease and some frontotemporal dementias, and some of this tau protein leaks out of the brain into the blood," said Tara Spires-Jones, the deputy director of the Centre for Discovery Brain Sciences at the University of Edinburgh, who was not involved in the study.The researchers report the blood test can distinguish Alzheimer's disease from other types of dementia and Parkinson's with a high degree of accuracy -- 89% to 98%.Additionally, measuring p-tau217 levels may also be able to detect brain changes 20 years before dementia symptoms occur."This test, once verified and confirmed, opens the possibility of early diagnosis of Alzheimer's before the dementia stage, which is very important for clinical trials evaluating novel therapies that might stop or slow down the disease process," the researchers, led by Dr. Oskar Hansson from Lund University in Sweden, wrote.Another study, published Tuesday in the Journal of Experimental Medicine, also verified that p-tau217 was more closely related to amyloid buildup in the brain than other chemicals that have been investigated."These two papers add to increasing evidence that modified tau proteins in the blood can accurately reflect Alzheimer's disease in processes occurring in the brain," said Amanda Heslegrave, a senior research fellow at the UK Dementia Research Institute at University College London, who was not involved in the study.In your doctor's officeThe formation of brain proteins, amyloid and tau, into clumps of amyloid plaques and tau tangles are defining physical features of Alzheimer's disease, but they are hard to detect without expensive PET scans or invasive spinal taps, neither of which is routinely covered by insurance.Doctors are left with verbal and written tests of memory and cognitive impairment, combined with interviews with patients' family members and caregivers about their behavior. That approach makes it tough to accurately diagnosis Alzheimer's...

Desperate to understand more about my mom's journey, I found Teepa Snow and her Positive Approach to Care. I devoured Teepa's free videos on YouTube, of course read her GEMS book and was eager for more. I signed up for her two-day, in real life Certified Training course and learned how to connect with my mom in a way I thought was no longer possible. When Teepa came to California, I was thrilled that she was willing to sit down and talk about her vast experience with people living with dementia and what she's seen with respect to how cannabis helps or hurts. With her no nonsense style, Teepa likens vanilla extract to CBD - not all are created equal. Teepa reminds us that we don't have other options and asks us to consider “What's the harm?...when pain is unremitting, and sleep won't come...people try things…I have seen remarkable differences...” We touch on a couple of the studies underway around the world, check em out if you like: King's College London will examine if Sativex is effective in treating agitation and aggression in dementia. They will recruit people ages 55-90 living with dementia in care homes. “Sativex® is a peppermint-flavoured mouth spray that contains a 1:1 ratio of two key cannabinoids found in the cannabis plant – delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).” Alzheimer's Society Canada has two studies under way, and this one presented results at the 2018 Alzheimer's Association International Conference in Chicago, IL. http://alzheimersocietyblog.ca/clearing-the-air-about-cannabis-and-dementia/ We hope you find EP2 with Teepa Snow interesting! Please share, subscribe, rate and review to learn more about how cannabis helps dementia. In Solidarity, Chela THANK YOU! Teepa Snow Anchor.fm Society of Cannabis Clinicians Opening music “Wishful Thinking” by Dan Lebowitz ...and thank you Mom, my greatest teacher. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/cannabishelpsdementia/message Support this podcast: https://anchor.fm/cannabishelpsdementia/support

Claire E. Day, Chief Program Officer, Alzheimer's Association Northern California and Northern Nevada Chapter, joins us to share updates from this year's Alzheimer's Association International Conference®. --- Send in a voice message: https://anchor.fm/caring-conversations/message

Dr. Jason Flatt, assistant professor at the UCSF School of Nursing's Institute for Health & Aging, will discuss some of the new research findings he presented at the July 2019 Alzheimer's Association International Conference in Los Angeles. Past research has shown an increased likelihood of preclinical Alzheimer's disease for individuals with self-reported memory problems, including up to three times greater risk for future cognitive decline. Dr. Flatt will highlight his recent research on Alzheimer's risk in the LGBTQ community and touch on the needs for education of health-care professionals and LGBTQ seniors as well as ensuring cognitive and health screenings for LGBTQ community members at risk for Alzheimer's disease. Join us as Michelle Meow brings her long-running daily radio show to The Commonwealth Club one day each week. Meet fascinating—and often controversial—people discussing important issues of interest to the LGBTQ community, and have your questions ready. Learn more about your ad choices. Visit megaphone.fm/adchoices

Pamela Atwood-Gerontologist and Executive Director of Colebrook Village at Hebron and Christy Kovel-Gerontologist and Director of Public Policy at the Alzheimer's Association Connecticut Chapter.Christy attended the Alzheimer's Association International Conference in Chicago in July. More than 5600 researchers, many from Connecticut were in attendance. They discussed best practices and the results of their ongoing research.

Two renowned Alzheimer's researchers and a clinical trial participant share their top takeaways from the Alzheimer’s Association International Conference, the largest gathering of Alzheimer’s researchers from across the world. They shared insights related to Alzheimer’s disparities impacting communities of color and about patient-centered research. Support the show (https://www.usagainstalzheimers.org/ways-donate)

Ryan Christensen, account executive at Adviser Investments, has the market analysis for Tuesday, July 24. The Dow Jones Industrial Average and S&P 500 gained 0.8% and 0.5%, respectively, while the NASDAQ Composite declined fractionally. For earnings, we saw Biogen (ticker: BIIB) top expectations with 15% earnings per share growth and 9% revenue advances. BIIB closed the day up nearly 6%. Investors continue to react favorably to Biogen’s stock as the company is scheduled to present clinical trials on its experimental BAN2401 therapy at this week’s Alzheimer’s Association International Conference.

Whilst at the Alzheimer’s Association International Conference in London (AAIC; UK, 16–20 July 2017), Lauren Pulling (Editor, Neuro Central) sat down with Kim Mueller, a researcher from the Wisconsin Alzheimer’s Institute (University of Wisconsin-Madison, WI, USA), whose abstract had been highlighted by the Association as one of note. The work presented at AAIC investigated whether early memory decline correlates with changes in everyday speech. The results showed that subtle changes in speech – e.g., the use of short sentences, more pronouns, more frequent pauses and filler words – increased in line with development of early mild cognitive impairment, and therefore, further down the line, could be used as a marker for Alzheimer’s disease. In this podcast, Kim discusses the study and its implications, including how these findings could one day be translated into new – potentially mobile – technology for at-home screening and disease monitoring. You can view more podcasts, plus the latest news and interviews with experts across neurology and neuroscience, at www.neuro-central.com.

Steve Ritz-Founder, Fitness First Too much exercise, for some, can cause muscles to die and put a strain on organs. Learn what this is and how to prevent it. Dr. Michael Rosenbloom-Health Partner’s Center for Dementia and Alzheimer’s Care in Neurology Dept. Also, on the Alzheimer’s Association of MN and ND Chapter Medical and Scientific Advisory Council The Alzheimer’s Association International Conference took place last week. What are some of the latest finds coming out of that conference?

*Did you know that the back is the most common location for the deadliest form of skin cancer? Board-certified dermatologist Dr. Lauren Ploch joins your national award-winning family radio talk show Let's Talk America with Host Shana Thornton to discuss melanoma and more. The Alzheimer’s Association International Conference recently wrapped up in Washington, DC. Dr. Heather Snyder, Director of Medical and Scientific Operations at the Alzheimer’s Association, joins the show to reveal the latest research developments. Dr. Juan Ochoa and dietitian Samantha Lynch join the show to spotlight baby boomer nutrition. Lastly, Dr. Jen Arnold will talk to Shana about childhood vaccinations. You will want to hear the latest in medical news. Join us and tell a friend.     *Please visit www.letstalkamericawithshanathornton.com. Thank you. 

Dr. Alex Pattakos talks about his own search for meaning, the experience that led to meeting Viktor Frankl, as well as offering a personal perspective on the choice we all have to discover meaning in every moment and situation.